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Abstract
Introduction Riboflavin (vitamin B2) is absorbed in the
small intestine by the human riboflavin transporters
RFVT1 and RFVT3. A third riboflavin transporter
(RFVT2) is expressed in the brain. In 2010 it was dem-
onstrated that mutations in the riboflavin transporter genes
SLC52A2 (coding for RFVT2) and SLC52A3 (coding for
RFVT3) cause a neurodegenerative disorder formerly
known as Brown-Vialetto-Van Laere (BVVL) syndrome,
now renamed to riboflavin transporter deficiency. Five
years after the diagnosis of the first patient we performed
a review of the literature to study the presentation, treat-
ment and outcome of patients with a molecularly con-
firmed diagnosis of a riboflavin transporter deficiency.
Method A search was performed in Medline, Pubmed using
the search terms ‘Brown-Vialetto-Van Laere syndrome’ and
‘riboflavin transporter’ and articles were screened for case
reports of patients with a molecular diagnosis of a riboflavin
transporter deficiency.
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B2) is a water soluble vitamin which is the precursor of the
active coenzymes flavin mononucleotide (FMN) and flavin
adenine dinucleotide (FAD), important cofactors for carbohy-
drate, amino acid and lipid metabolism (Lienhart et al. 2013).
Humans depend on the dietary intake of riboflavin from milk,
meats, fatty fish and green vegetables and the recommended
daily allowance of Riboflavin varies from 0.4 mg (infants) to
1.6 mg (lactating women) (Powers 2003). Excess riboflavin,
FAD and FMN are excreted in the urine. Besides the major
supply from the diet unknown amounts of riboflavin are
generated by bacteria and absorbed in the large intestine
(Said 2015).
Results Reports on a total of 70 patients with a molec-
ular diagnosis of a RFVT2 or RTVT3 deficiency were
retrieved. The riboflavin transporter deficiencies present
with weakness, cranial nerve deficits including hearing
loss, sensory symptoms including sensory ataxia, feed-
ing difficulties and respiratory difficulties which are
caused by a sensorimotor axonal neuropathy and cranial
neuropathy. Biochemical abnormalities may be absent
and the diagnosis can only be made or rejected by mo-
lecular analysis of all genes. Treatment with oral sup-
plementation of riboflavin is lifesaving. Therefore, if a
riboflavin transporter deficiency is suspected, treatment
must be started immediately without first awaiting the
results of molecular diagnostics.
Riboflavin transporters
Riboflavin is a well-known chaperone effective in the treat-
ment of inborn errors of metabolism such as MADD and
mitochondrial disorders (Cornelius et al. 2012; Carrozzo
et al. 2014). Only since 2010 there is insight into inborn errors
of riboflavin transport (Green et al. 2010; Bosch et al. 2011;
Bosch et al. 2012; Foley et al. 2014). Presently three riboflavin
transporters have been characterized: RFVT1 mostly
expressed in small intestine, RFVT 2 mostly expressed in
the brain and RFVT 3 mostly expressed in the small intestine
(Fig. 1, adapted from Yonazawa 2013) (Yonezawa et al. 2008;
Yamamoto et al. 2009; Yao et al. 2010).
Riboflavin transporter deficiency
In 2010 it was demonstrated that mutations in the riboflavin
transporter genes SLC52A2 (coding for RFVT2) and
SLC52A3 (alias C20orf54, coding for RFVT3) are the cause
of the neurodegenerative disorder formerly known as Brown-
Vialetto-Van Laere (BVVL) or Fazio Londe (FL) syndrome
(Green et al. 2010; Bosch et al. 2011). Remarkably, except for
one report of riboflavin deficiency in an infant of a mother
with one mutation in the RFVT1 gene, no patients with
RFVT1 deficiency have been reported in the literature.
Inheritance of RFVT2 and RFVT3 deficiency is au-
tosomal recessive. A literature review of 75 patients
with BVVL or FL syndrome demonstrated that patients
may present at all ages, with a variable but mostly rapid
progression and a fatal outcome if untreated, with the
most severe course in the youngest age groups. Our
index patient presented at the age of 6 months with
muscle weakness and diaphragmatic paralysis necessitat-
ing artificial ventilation and a tracheotomy (Bosch et al.
2011). Presenting symptoms of patients included in the
review were severe axial and limb weakness, bulbar
palsy, hearing loss, facial weakness and respiratory com-
promise (Bosch et al. 2012). Some patients with a mo-
lecularly confirmed diagnosis demonstrated abnormal
plasma flavin levels and/or plasma acylcarnitine profiles,
rapidly reversible with supplementation of riboflavin.
Treatment with high dose oral riboflavin was effective
and lifesaving. However, this review reported on pa-
tients with a possibly diverse etiology as only in 23/
75 reported patients the diagnosis was confirmed with
molecular analysis. Since then, more patients with a
molecular diagnosis have been reported in the literature.
Five years after the diagnosis of our index patient we
performed a review of the literature to study the presen-
tation, treatment and outcome of patients with a molec-
ularly confirmed diagnosis of a riboflavin transporter
deficiency aiming to extend our insight into this new
inborn error of metabolism.
Methods
A search was performed in Medline, Pubmed using the search
terms ‘Brown-Vialetto-van Laere syndrome’ and ‘riboflavin
transporter’. The publications found were studied for case
reports of patients with a molecular diagnosis of a riboflavin
transporter deficiency. All case reports were analyzed for clin-
ical aspects, additional investigations, survival and treatment.
Patients describedmore than one time in different reports were
included once.
Results
The search strategy identified 45 articles of which 19 articles
reported on patients with a molecular diagnosis of a riboflavin
transporter deficiency. After exclusion of duplicates 70 report-
ed patients (42/70 (60 %) females and 28/70 (40 %)males)
with either compound heterozygous or homozygous muta-
tions in SLC52A2 or SLC52A3 were included in the review.
Of these, 37 patients (53 %) were diagnosed with a RFVT2
deficiency (SLC52A2) (Johnson et al. 2012; Haack et al.
2012; Ciccolella et al. 2012; Foley et al. 2014; Srour et al.
2014; Menezes et al. 2016) and 33 (47 %) with a RFVT3
deficiency (SLC52A3) (Green et al. 2010; Johnson et al.
Fig. 1 riboflavin transport
(adapted from Yonazewa et al.
2008)
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2010; Bosch et al. 2011; Anand et al. 2012; Koy et al. 2012;
Dezfouli et al. 2012; Ciccolella et al. 2013; Bandettini Di
Poggio et al. 2014; Spagnoli et al. 2014; Cosgrove et al.
2015; Davis et al. 2015; Horoz et al. 2015; Spagnoli and De
Sousa 2012).
Age and symptoms at presentation
The mean age of presentation was 4.1 years (range 0.25–
27.0 years; SD 5.0) for the total group, 3.0 years (range
(0.6–8.0 years; SD 1.7) for the RFVT2 deficient patients and
5.6 years (range 0.25–27.0 years; SD 7.0) for the RFVT3
deficient patients. Main presenting symptoms included hear-
ing loss, weakness of limbs and neck, bulbar weakness lead-
ing to feeding difficulties, balance and gait problems and re-
spiratory complaints like dyspnea or stridor. Less frequently
visual problems and problems with speech were reported.
Clinical features
During the course of illness most reported symptoms were
cranial nerve deficits resulting in hearing loss and bulbar
symptoms, weakness and sensory symptoms. Feeding diffi-
culties and respiratory symptoms occurred secondary to bul-
bar and respiratory muscle weakness (Table 1). Remarkably,
cognition was reported to be normal in 29 patients and no
cognitive abnormalities were reported in any of the patients.
Cranial nerve deficits
Sensorineural hearing loss was reported in 58/70 patients at
presentation or during the course of their disease.
Abnormalities of all other cranial nerves were reported. It
was not possible to specify the frequency of involvement of
each cranial nerve, but bulbar symptoms due to dysfunction of
cranial nerves VII-XII were reported in the majority of pa-
tients. Reduced vision and or optic atrophy were reported in
26/37 (70%) patients with RFVT2 deficiency but only in 2/33
patients (6 %) with RFVT3 deficiency.
Weakness
Limb weakness (frequently accompanied by atrophy) was re-
ported in 53/70 patients and described in most detail in pa-
tients with RFVT2 deficiency. In 34/37 (92 %) patients with
RFVT2 deficiency the muscles in the upper extremities were
more involved than the lower extremities and most patients
suffered from shoulder girdle and distal hand muscle weak-
ness. Many also developed axial weakness, with severe weak-
ness of neck extensor and trunk muscles resulting in scoliosis
in six patients (Johnson et al. 2012; Srour et al. 2014). In
RFVT3 deficient patients more variable patterns of weakness
were reported. Reflexes were reported in 25 RFVT2 deficient
patients and were hypoactive or absent. Of four patients with
RFVT3 deficiency two patients demonstrated normal reflexes,
one hypoactive reflexes and one brisk deep tendon reflexes
with an ankle clonus (Green et al. 2010).
Sensory symptoms
In a minority of cases sensory abnormalities were an isolated
finding with a more severe disturbance of vibration- and po-
sition sense than loss of sensation for pain and touch (Srour
et al. 2014). An ataxic gate was reported in 19/37 (51 %)
patients with RFVT2 deficiency (Foley et al. 2014; Srour
et al. 2014; Menezes et al. 2016). These patients had a con-
firmed sensorimotor axonal neuropathy and no weakness in
the lower limbs or cerebellar signs, therefore a disturbed pro-
prioception due to a progressive sensory neuropathy or
neuronopathy seemed the cause of this gait disorder. In 5/33
patients with RFVT3 deficiency gait or truncal ataxia was
described, without information on the presence or absence of
a neuropathy (Green et al. 2010; Malafronte et al. 2013).
Cerebellar signs were reported in one RFVT3 deficient patient
described by Green et al.
Feeding difficulties
In 27 (RFVT2: 18; RFVT3: 9) patients information on feeding
was provided (Johnson et al. 2010; Koy et al. 2012; Ciccolella
Table 1 Reported clinical
features in patients with RFVT2
and RFVT3 deficiency
Clinical feature RFVT2 deficiency





Cranial nerve deficit 27 (73 %) 25 (76 %) 52 (74 %)
Hearing loss 33 (89 %) 25 (76 %) 58 (73 %)
Weakness 34 (92 %) 24 (73 %) 58 (73 %)
Sensory symptomsa 19 (51 %) 5 (15 %) 24 (34 %)
Feeding difficulties 9 (24 %) 8 (24 %) 17 (24 %)
Respiratory symptoms 21 (57 %) 25 (75 %) 46 (66 %)
a Including ataxic gait without other cerebellar signs or muscle weakness in lower limbs in patients with con-
firmed sensorimotor axonal neuropathy
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et al. 2013; Foley et al. 2014; Bandettini Di Poggio et al. 2014;
Spagnoli et al. 2014; Cosgrove et al. 2015). Feeding difficulties
were present in 8/18RFVT2deficient patients and in 9/9RFVT3
deficient patients. In 16/17 patients the feeding difficulties neces-
sitated a gastronasal or PEG tube to secure feeding.
Respiratory symptoms
Respiratory problems were reported in 21/37 (57 %) patients
with RFTV2 deficiency and in 25/33 (76 %) patients with
RFVT3 deficiency (Green et al. 2010; Johnson et al. 2010;
Bosch et al. 2011; Anand et al. 2012; Koy et al. 2012;
Dezfouli et al. 2012; Johnson et al. 2012; Ciccolella et al.
2012; Ciccolella et al. 2013; Foley et al. 2014; Spagnoli
et al. 2014; Cosgrove et al. 2015; Davis et al. 2015; Horoz
et al. 2015). Respiratory symptoms developed during the
course of the disease in most patients but were a presenting
symptom in two and eight RFVT2 and RFVT3 deficient pa-
tients respectively. Diaphragm paralysis was documented in
four patients with RFVT3 deficiency. Artificial respiratory
support was required in 15/23 (65 %) RFVT2 deficient pa-
tients and in 9/22 (41 %) RFVT3 deficient patients.
Biochemical abnormalities
Acylcarnitine profiles were reported in 28 RFTV2 deficient
patients and in 8 RFVT3 patients and were abnormal in 17/28
(61 %) and 4/8 (50 %) respectively. All abnormal




In 16 (RFVT2:6; RFVT3:10) patients a cranial MRI was
made. All cranial MRI’s in RFVT2 deficient patients were
normal. Abnormalities were found in 2/10 patients with
RFVT3 deficiency: one patient demonstrated increased signal
intensities of the vestibular nuclei, the cerebellar superior pe-
duncle and central tegmental tract (Koy et al. 2012), another
showed symmetrical, hyperintense areas in the middle cere-
bellar peduncles on T2 FLAIR images (Bandettini Di Poggio
et al. 2014).
Neurophysiology
An EMG was performed in 42 patients (SLC52A2: 32;
SLC52A3: 10). In 32/32 (100 %) RFVT2 deficient patients
and 2/10 RFVT3 deficient patients the authors reported find-
ings consistent with a sensorimotor axonal neuropathy. In the
majority of RFVT2 deficient patients sensory findings were
more pronounced than motor findings. Sensory nerve action
potentials (SNAP) were absent in most patients and com-
poundmotor action potential (CMAP) amplitudes were absent
or decreased in arms and legs. Reported motor nerve conduc-
tion velocities were mildly slowed or normal. In 1/10 RFVT3
deficient patients the neurophysiological exam was normal, in
7/10 described as motor neuropathy or motor neuron disease.
Histopathology
A sural nerve biopsy, taken in 8 RFVT2 deficient patients
showed signs of a chronic axonal neuropathy in 7/8 patients
with preferential loss of large diameter myelinated axons, in
accordance with the clinical finding of sensory ataxia
(Johnson et al. 2012; Haack et al. 2012; Foley et al. 2014;
Srour et al. 2014). A sural nerve biopsy taken from a patient
with RFVT3 deficiency revealed signs of a motor
neuronopathy and axonal degeneration (Johnson et al. 2010).
Treatment
A total of 31 patients was not treated with riboflavin supple-
mentation and these patients all demonstrated a gradual dete-
rioration (Green et al. 2010; Johnson et al. 2010; Dezfouli
et al. 2012; Johnson et al. 2012; Ciccolella et al. 2012;
Malafronte et al. 2013; Ciccolella et al. 2013; Bandettini Di
Poggio et al. 2014; Srour et al. 2014). Fifteen patients
(RFVT2: 6; RFVT3: 9) were reported to have died at the time
of publication. The cause of death was reported in nine pa-
tients, seven patients died of respiratory insufficiency, and the
cause of death was not clearly reported in 2. Mean age be-
tween onset of symptoms and death was 7.11 years (range
0.6–19.0 years).
In 39 (RFVT2: 27; RFVT3: 13) patients treatment with oral
riboflavin was started in a dosage ranging from 7 to 60 mg/kg/
day (Bosch et al. 2011; Anand et al. 2012; Koy et al. 2012;
Haack et al. 2012; Foley et al. 2014; Spagnoli et al. 2014;
Cosgrove et al. 2015; Menezes et al. 2016; Davis et al.
2015; Horoz et al. 2015). Side effects were reported in three
patients and included gastrointestinal symptoms. No death
after the start of treatment has been reported. Clinical response
was reported in 20 RFVT2 deficient patients. Twelve patients
(60 %) improved, eight patients (40 %) remained stable after
initiation of riboflavin. In one RFVT3 deficient patient ribo-
flavin was stopped after 1 week because of lack of a clinical
response. In ten patients with RFVT3 deficiency clinical re-
sponse was documented. Eight improved (80 %), 2 (20 %)
remained stable. Improvement occurred within days to
months in both types of riboflavin deficiency. In the remaining
patients the effect of riboflavin was not mentioned.
In 15 RFVT2 deficient patients age at the start of treatment
with riboflavin and response to treatment were reported (Foley
et al. 2014). Mean time between onset of symptoms and start
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of treatment in the RFVT2 deficient patients that remained
stable after initiation of riboflavin was 19.2 years (range
1.9–50.0 years, SD 16.9), in the patients that improved
7.4 years (range 0.5–20.6 years, SD 7.3). Information on time
between onset of symptoms and start of treatment and re-
sponse to treatment was available in 6 RFVT3 deficient pa-
tients (Bosch et al. 2011; Anand et al. 2012; Ciccolella et al.
2013; Spagnoli et al. 2014). Mean time between onset of
symptoms in the five patients that improved was 3.1 years
(range 0.1–14 years, SD 6.1). One patient did not improve
after 1 year of treatment with riboflavin (Davis et al. 2015).
Discussion
We performed a review of the literature aiming to obtain better
insight in the presentation, treatment and outcome of patients
with a molecularly confirmed diagnosis of a riboflavin trans-
porter deficiency type two (RFVT2) or three (RFVT3).
Including the first reports of riboflavin transporter deficiencies
in 2010, 70 case reports have been published.
The presenting age of the patients was variable with the
oldest patient presenting at the age of 27 years but most pa-
tients presenting in the first years of life. Reported clinical
symptoms were hearing loss, weakness, cranial nerve deficits,
sensory symptoms including sensory ataxia, feeding difficul-
ties and respiratory problems (frequently due to diaphragmatic
paralysis), which was comparable to our previous review of a
possibly more heterogeneous cohort of patients (Bosch et al.
2012). No cognitive abnormalities were reported in any of the
patients. Our results confirm the proposal of Foley et al.
(2014) that sensory ataxia and optic atrophy seem more prev-
alent in RFVT2 than RFVT3 deficient patients (62 % vs 6 %
and 70 % vs 6 % respectively). However, patient numbers are
small and not all symptoms may have been reported for all
patients. Future studies are necessary to further explore differ-
ences between RFVT2 and RFVT3 deficiency.
While starkly abnormal acylcarnitine profiles led to the
diagnosis in our index patient, only approximately half of
the reported patients demonstrated abnormalities in their
acylcarnitine profile at diagnosis which confirms our previous
report that acylcarnitine profiles are not a valid instrument for
the diagnosis of riboflavin transporter deficiencies (Bosch
et al. 2011; Bosch et al. 2012). In the past 5 years more insight
has been obtained into the pathophysiology of this disorder.
Neurophysiological and histopathological studies almost in-
variably demonstrated findings consistent with an axonal sen-
sorimotor peripheral neuropathy in RFVT2, confirming the
report of Foley et al. (2014). Data on neurophysiology and
histopathology in RFVT3 are scarce but point to a sensorimo-
tor neuropathy in some patients. In addition clinical findings
in both RFVT2 and RFVT3 indicate involvement of cranial
nerves. The underlying pathophysiological mechanism of this
neuropathy or neuronopathy remains to be elucidated. Only
one RFVT3 deficient patient showed signs of upper motor
neuron involvement.
Treatment with oral riboflavin supplementation (doses
varying from 7 to 60 mg/kg/day) was initiated in 39/70 pa-
tients. All 31/70 untreated patients suffered from progression
of the disease, resulting in death (mostly from respiratory in-
sufficiency) in 15/31 patients at the time of the publication. In
contrast, no death was reported in the cohort of 39 treated
patients and in those patients in whom effects of treatment
were reported 71 % demonstrated clinical improvement and
29 % a stabilization of symptoms. Clinical improvement may
occur within days to months after start of treatment and an
earlier start of treatment seems associatedwith better andmore
rapid improvement suggesting that prolonged disease may
result in irreversible damage.
Challenges
At this time our insight into these severe neurodegenerative
disorders is very limited and many questions remain to be
answered. The exact pathophysiology is still unclear. The
spectrum of disease is unknown and while most reported pa-
tients were diagnosed with severe disease at a very young age,
there may well exist a larger cohort of patients with a milder
phenotype who might benefit greatly from early treatment.
The optimal dosing of oral riboflavin is unknown and patients
have been reported to recover well on doses varying from 7 to
60 mg/kg/day. In the 16 patients that received riboflavin ther-
apy described in the study by Foley et al. doses varied be-
tween 10 and 60 mg/kg/day. In the majority of these patients
riboflavin was started at a dose of 20–40mg/kg/day. Presently,
the authors prescribe 20 mg/kg/day with a maximum of 3dd
400 mg. Ultimately, it is not clear whether the riboflavin sup-
plementation will be effective in preventing symptoms for life
or whether it may simply delay the occurrence of symptoms,
especially in our youngest patients.
Until now the disease course of our index patient is
encouraging. After presenting at the age of 6 months
with severe generalized weakness and diaphragmatic pa-
ralysis necessitating artificial ventilation our patient
slowly recovered after the start of riboflavin supplemen-
tation (Bosch et al. 2011). After 16 months of treatment
with oral riboflavin in a dose of 10 mg/kg/day (age
22 months) he was able to walk independently.
Respiratory support could be decreased over time and
the tracheotomy was closed at age 4 years. At age nine
he demonstrates a fully normal neurological examination
and normal strength. His sister, presenting at age
3 months with axial weakness, recovered within 7 days
of start of treatment and demonstrates a normal devel-
opment at age 6 years.
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Conclusion
The riboflavin transporter deficiencies present with cranial
nerve deficits including hearing loss, weakness, sensory symp-
toms including sensory ataxia, feeding difficulties and respira-
tory difficulties which are caused by a progressive axonal sen-
sory and motor peripheral neuropathy and a cranial neuropathy.
The diagnosis can only be made through molecular analysis of
all genes. Treatment with oral supplementation of riboflavin is
lifesaving. Therefore, treatment must be started immediately if
a riboflavin transporter deficiency is suspected, without first
awaiting the results of molecular diagnostics.
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